

## HIGHLIGHTS

- Nonalcoholic fatty liver disease has been renamed metabolic dysfunction-associated steatotic liver disease (MASLD)
- MASLD and chronic kidney disease (CKD) are two conditions dramatically increasing worldwide.
- Evidence supports an association between MASLD and risk of developing CKD.
- The magnitude of this risk increases with severity of liver disease.
- Certain drugs used for treatment of diabetes improve MASLD and reduce the related risk of CKD.